Kratom Scientists Issue Statement on Regulation: Key Findings Revealed! The statement highlights the most important conclusions from research: • Mitragynine is the major alkaloid in kratom and because of this, it has been the subject of most scientific reports; • Mitragynine is not a classical opioid, like morphine, but rather is unique in that it has partial agonist activity and relatively low abuse liability; • With a diverse kratom product marketplace in the US, it is important to distinguish between products; • In the years that kratom whole leaf and extract products have been sold in the US, there have been, to date, few clinical case reports of adverse effects; By highlighting the distinct characteristics of mitragynine and the limited adverse effects reported from kratom products, it provides a nuanced understanding of the plant’s potential benefits and risks. Moving forward, informed regulatory decisions should consider the scientific evidence presented, ensuring the responsible use and availability of kratom products while prioritizing public safety. https://lnkd.in/gCKw8h6F
Melody Woolf’s Post
More Relevant Posts
-
Kratom Scientists Issues Statement on Regulation: 🍃Mitragynine major alkaloid in kratom and because of this, it has been subject of most scientific reports; 🍃Mitragynine is not classical opioid, like morphine, but rather is unique it has partial agonist activity and relatively low abuse liability; 🍃With a diverse kratom product marketplace in the US, it is important to distinguish between products; 🍃In the years that kratom whole leaf and extract products have been sold in the US, there have been, to date, few clinical case reports of adverse effects; 🍃By highlighting the distinct characteristics of mitragynine and the limited adverse effects reported from kratom products, it provides nuanced understanding of the plant’s potential benefits and risks. Moving forward, informed regulatory decisions should consider the scientific evidence presented, ensuring the responsible use and availability of kratom products while prioritizing public safety. https://lnkd.in/gCKw8h6F
-
-
Kratom Scientists Issues Statement on Regulation: 🍃Mitragynine major alkaloid in kratom and because of this, it has been subject of most scientific reports; 🍃Mitragynine is not classical opioid, like morphine, but rather is unique it has partial agonist activity and relatively low abuse liability; 🍃With a diverse kratom product marketplace in the US, it is important to distinguish between products; 🍃In the years that kratom whole leaf and extract products have been sold in the US, there have been, to date, few clinical case reports of adverse effects; 🍃By highlighting the distinct characteristics of mitragynine and the limited adverse effects reported from kratom products, it provides nuanced understanding of the plant’s potential benefits and risks. Moving forward, informed regulatory decisions should consider the scientific evidence presented, ensuring the responsible use and availability of kratom products while prioritizing public safety. https://lnkd.in/gCKw8h6F
-
-
Excited to share my 1st review article, "EXPLORING THE THERAPEUTIC POTENTIAL OF DRAGON FRUIT- AN INSIGHTFUL REVIEW." Published in #International #Journal of #Pharmacognosy (2024), Volume 1, Issue 6 #PharmaceuticalResearch #DrugDevelopment #ReviewArticle
-
-
Check out the fascinating insights in this white paper by Margaret (Meg) Richards, PhD, MPH as she dives into the challenging journey toward developing weight loss drugs. https://lnkd.in/gEhefQv3 #WeightLoss #WeightLossDrugs #Wegovy
-
-
Download the new case study! https://lnkd.in/d6UvN43R With drug fatalities increasing globally, there is an urgent need for faster screening in emergency settings. Learn how the #forensics lab at King’s College London is utilizing Thermo Scientific #VeriSpray PaperSpray mass spectrometry to accelerate drug toxicity screening and advance point-of-care solutions. Advantages of this approach: · Easy to use · Reduced risk of cross contamination · Fast turnaround time for high-throughput screening · Improved healthy outcomes for individuals with drug toxicity!
-
-
Dermatology Resident, Host of Cutaneous Miscellaneous Podcast, Host of Under Your Skin and Dermbusters, Previous Fellow in Clinical Research/Psoriasis/Phototherapy/Melanoma
Check out my new paper on the first reported case in the literature of drug induced AA from upadacitinib, curious to hear from my derm colleagues if they have experienced anything similar in their patients. I think we have a valid argument in this case report regarding this unexpected occurence! Read here: https://lnkd.in/eAyduyi9
-
-
Understand the medicinal potential and toxicological aspects of Podophyllum peltatum with this brand-new review: https://lnkd.in/d5gaJdqx #Podophyllumpeltatum #PharmacolRes #ModernChineseMedicine #Research
-
-
Control of potentially mutagenic impurities is an important consideration when devising control strategies for drug substances. The ICH M7 guideline provides the framework for this topic. A group of subject matter experts across industry, including myself recently published an article, highlighting utilization of Option 3 or 4 control strategies. The article is now available in Organic Process Research & Development. Congratulations to my co-authors on getting this work published. Mike Urquhart, Michael Burns, Hugh Clark, Jean-Philippe C., Olivier Dirat, Stefan Hildbrand, Christian Moessner, David Pascoe, Alastair Roberts, and Andrew Teasdale. #processchemistry, #controlstrategy, #ICHM7 https://lnkd.in/eQCKKg9W
-
Publisher / Sr. Business Development Manager , B2B Media Sales: Pharmaceutical Online , CellandGene- Life Science Connect Media
This August 20th webinar on "What to do with Unexpected Positive Biological Indicator (BI) Results" seems like a valuable opportunity for those dealing with disruptions in sterilization processes. Here are some key details about the webinar: Date and Time: August 20th at 1:00 PM (EST) / 12:00 PM (CST), lasting for 45 minutes. Speaker: Maria Luisa Bernuzzi, an expert from Mesa Laboratories, Inc. Labs with extensive experience in the industry. Webinar Topics: Understanding positive BIs, best practices for investigation, common causes, and prevention. Benefits of Attending: Learning from an industry expert, gaining the latest tools and techniques, optimizing sterilization processes, and receiving valuable resources. To register for the webinar and secure your spot, visit the registration page provided by Mesa Labs. This webinar could help you enhance your knowledge and skills in managing unexpected positive BI results effectively. #webinar #sterilization #biologicalindicators #pharma
-
Another paper under the supervision of Barbara Jadach in cooperation with Anna Froelich, Adam Tatarek and Tomasz Osmałek has just been accepted for publication in Journal of Drug Delivery and Science and Technology. 🤝👍 This time we have described the methods used to increase the dissolution rate of meloxicam. We wish you a pleasant reading!! 📖 https://lnkd.in/duuEFysE #meloxicam #dissolution #oraldrugs
-
--
6moAfter Claudia Merandi was mentioning the RI ban . . . I ordered from a reliable source & was uniquely surprised that it worked for me. A lot of supplements promise that & don't do that. Just the small amount it works is a godsend. I can't tolerate it drinking the powder. But, tolerate the cables very well. Thank you Claudia!